ODTX
Odyssey Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.76
+8.94%Aug 6, 2026, 06:16 UTC
Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics to discover new treatments for autoimmune and inflammatory diseases using Evotec's AI-enabled discovery platform.
Source:Aug 4, 2026, 00:00 UTC
Odyssey Therapeutics reported a GAAP net loss of $52.8 million for Q2 2026, compared to a net loss of $41.2 million in Q2 2025, with cash and marketable securities of $433.1 million as of June 30, 2026.